





To the Editor: Nordmann 
et al. (1) raised concern over the 
global spread of carbapenemase-
producing Enterobacteriaceae. In 
their article, they called attention to 
the oxacillinase-48 (OXA-48) type 
carbapenemases because bacteria 
that produce these enzymes do not 
have a distinctive antimicrobial drug 
susceptibility profi le, and there is 
less awareness of this mechanism of 
carbapenem resistance. We report the 
recent isolation of blaOXA-181–positive 
Klebsiella pneumoniae from 2 patients 
from Bangladesh who were admitted 
to separate hospitals in Singapore 
within a short period of each other.
The fi rst patient was a 64-year-
old man who had a recent heart attack 
and was transferred from a hospital 
in Dhaka, Bangladesh, to a hospital 
in Singapore for treatment for 
pancytopenia. He had no other history 
of recent travel. While in Bangladesh, 
the patient had Pseudomonas 
spp. bacteremia and had received 
meropenem and vancomycin. In 
Singapore, his antimicrobial drug 
treatment regimen was changed 
to ciprofl oxacin, linezolid, and 
amikacin. Blood samples obtained on 
the day of admission were cultured 
and grew a vancomycin-resistant 
Enterococcus spp. and a carbapenem-
resistant K. pneumoniae (isolate 
DB53879_11).
Two days after admission, when 
the results of his blood culture were 
known, the patient’s antimicrobial 
drug treatment regimen was changed 
to oral linezolid (600 mg every 
12 hours), intravenous tigecycline 
(initially 50 mg every hour but 
later increased to 100 mg every 12 
hours), and intravenous polymyxin E 
(initially 3 MU/d but later increased to 
3 MU every 12 hours). Blood cultured 
for K. pneumoniae showed positive 
results for 5 days after the patient was 
hospitalized before clearing.
Isolate DB53879_11 was 
resistant to many antimicrobial drugs 
as determined by Etest (bioMérieux, 
Marcy l’Etoile, France) (Table). It was 
strongly positive for carbapenemase 
production as determined by use of a 
modifi ed Hodge test (2) and showed a 
negative result with the KPC + MBL 
Confi rm ID Kit (Rosco Diagnostica 
A/S, Taastrup, Denmark).
Using PCR, we amplifi ed and 
sequenced a product identical to 
the complete sequence of blaOXA-181. 
Primers designed for known fl anking 
regions of blaOXA-181 (GenBank 
accession no. JN205800) failed to 
amplify any product. Like described 
isolates (3–5), DB53879_11 was also 
positive for blaOXA-1 and blaCTX-M-15, 
but it also was positive for blaCMY-4. An 
attempt to transfer blaOXA-181 to azide-
resistant Escherichia coli J53 by plate 
mating was unsuccessful.
Two weeks after we received the 
specimen from the fi rst patient, we 
were referred 2 carbapenem-resistant 
K. pneumoniae strains isolated from 
sputum (isolate DX1083_11) and 
blood (isolate BL21479_11) from a 
30 year-old man admitted to another 
hospital in Singapore. He had been 
treated in the same hospital in Dhaka 
as the fi rst patient for multiorgan 
failure secondary to dengue shock 
syndrome. Antimicrobial drug 
susceptibility phenotypes and 
resistance gene complements for 
DX1083_11 and BL21479_11were 
similar to those for the isolate from 
the fi rst patient. The second patient 
received intravenous tigecycline, 
polymyxin B, and meropenem.
All 3 isolates were identical 
when tested by random amplifi cation 
of polymorphic DNA (6) and by 
pulsed-fi eld gel electrophoresis after 
restriction endonuclease digestion 
of chromosomal DNA with SpeI. 
Multilocus sequence typing showed 
that DX1083_11 belonged to sequence 
type 14 (www.pasteur.fr/recherche/
genopole/PF8/mlst/Kpneumoniae.
html). This sequence type is the 
same as that for blaOXA-181–positive 
K. pneumoniae reported from New 
Zealand (3). Both patients died of 
their illnesses.
OXA-181 is a close relative of 
OXA-48 from which it differs by 4 aa 
(4). blaOXA-181–positive K. pneumonia 
infections were fi rst described in India 
but imported cases have since been 
described in Oman, the Netherlands, 
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DB53879_11 DX1083_11 BL21479_11 
Ampicillin 256 256 256 
Amoxicillin/clavulanate 256 256 256 
Piperacillin/tazobactam 256 256 256 
Cefuroxime 256 256 256 
Ceftriaxone 32 32 32
Ceftazidime 256 256 256 
Cefepime 256 256 256 
Ertapenem 32 32 32
Imipenem 16 32 16
Meropenem 32 32 32
Doripenem 32 32 32
Ciprofloxacin 32 32 32
Levofloxacin 32 32 32
Gentamicin 256 256 256 
Amikacin 256 256 256 
Sulfamethoxazole/trimethoprim 32 32 32
Tetracycine 256 256 8
Tigecycline 4 4 4 
Polymyxin B 0.5 1 4 
*OXA-181, oxacillinase-181. 
LETTERS
and New Zealand (3–5,7). We were 
unable to confi rm the original source 
of these isolates, and continuous 
surveillance for carbapenemase 
producers in our hospital has not 
uncovered any blaOXA-181–positive 
isolates since 1996. To our knowledge, 
there are no reports of blaOXA-181–
positive isolates in Bangladesh. 
However, this country borders India, 
which is a source of blaOXA-181–positive 
Enterobacteriaceae. These cases 
highlight potential problems that may 
arise from medical tourism (the rapidly 
increasing practice of traveling across 
international borders to obtain health 
care) and document the expanding 
range of a newly emerging mechanism 
of carbapenem resistance.
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Dengue Fever 
in South Korea, 
2006–2010
To the Editor: Dengue fever is 
an acute, febrile disease caused by a 
fl avivirus and is transmitted by Aedes 
spp. mosquitoes (1). South Korea is 
not considered as a region to which 
dengue virus is endemic because it 
is located above 35°N latitude and 
has an isotherm of 10°C in winter, 
which potentially limits year-round 
survival of Aedes aegypti mosquitoes 
(1,2). Thus, dengue fever was seldom 
recognized as a public health concern 
in South Korea. However, the fi rst 
case of dengue fever in South Korea 
was reported in 1995 in a woman 
who had traveled to Sri Lanka (3). A 
second case was found in a sailor who 
had worked in countries in Africa in 
2000 (4).
Since 2001, dengue fever has 
been a notifi able infectious disease 
in South Korea because of concerns 
about increasing international travel 
as a source of infection and because 
the less effi cient potential dengue 
vector, Ae. albopictus mosquitoes, 
were found in this country. All cases 
reported through the surveillance 
system should be complemented by 
thorough epidemiologic investigations 
to determine whether a case was 
imported or originated in South 
Korea. Thus, we analyzed dengue 
fever–associated data from the Korea 
Centers for Disease Control and 
Prevention.
During 2006–2010, a total of 
367 suspected cases were reported 
by physicians through the National 
Infectious Disease Surveillance 
System. IgM ELISA and reverse tran-
scription PCR results identifi ed 324 
cases as dengue fever. Investigation 
of 34 cases could not be completed 
because some cases were in foreigners 
and in Korean persons who resided 
in foreign countries, left South Korea 
after diagnosis, or could not be reached 
by the contact information that was 
provided. Investigation of 290 cases 
was completed by reviewing medical 
records and by interviews. Interviews 
were conducted by provincial and 
Korea Centers for Disease Control 
and Prevention Epidemic Intelligence 
Service offi cers, who used a 
standardized investigation form.
All 290 case-patients had a 
history of international travel before 
onset of dengue fever symptoms. 
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